1. A composition comprising three anti-EGFR antibodies, including a first antibody, the second antibody and a third antibody, wherein (i) the first antibody is the antibody selected from the group, or competes with EGFR antibody selected from the group, or binds to the the same epitope as an antibody selected from the group consisting of ca, cb and cc (Ii) the second antibody is an antibody selected from the group, or competes with EGFR antibody selected from the group, or binds to the same epitope as an antibody selected from the group consisting of cd, ce and cf and (iii) the third antibody is an antibody selected from the group, or competes with EGFR antibody selected from the group, or binds to the same epitope as an antibody selected from the group consisting of: cg, ch, ci, cj and ck.2. A composition according to claim 1, characterized in that (i) the first antibody is an antibody or competes with the EGFR with an antibody or binds to the same epitope as antibody ca (comprising a CDR 1, 2 and 3 of the heavy chain indicated in SEQ ID NO: 29, 30 and 34, respectively, and CDR 1, 2 and 3 of the light chain as defined in SEQ ID NO: 48, 45 and 49, respectively) (Ii) the second antibody is an antibody or competes with the EGFR with an antibody or binds to the same epitope as antibody cd (comprising a CDR 1, 2 and 3 of the heavy chain as defined in SEQ ID NO: 29, 30 and 31, respectively, and CDR 1, 2 and 3 of the light chain as defined in SEQ ID NO: 53, 54 and 55, respectively) (Iii) the third antibody is an antibody or competes with the EGFR with an antibody or binds to the same epitope as antibody ch (comprising a CDR 1, 2 and 3 of the heavy chain as defined in SEQ ID NO: 23, 24 and 26, respectively, and CDR 1, 2 and 3 of the light chain as defined in SEQ ID NO: 39, 40 and 42, respectively) .3. Use of a composition according to any of claims 1 or 2 for
